Loading
A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., active and no longer recruiting.
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06166836 by InxMed (Shanghai) Co., Ltd., with 140 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D1553 and IN10018（Ifebemtinib）.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InventisBio, IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InventisBio and the tag pipeline.
Shares IN10018 and the tag pipeline.
Shares IN10018 and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/